Investing.com — Vericel (NASDAQ:) Corporation shares fell 11% after market close as the company reported preliminary total revenue for the fourth quarter that did not meet the average analyst estimate.
The biopharmaceutical company’s preliminary total revenue fell between $75.2 million and $75.7 million, falling short of the estimated $77.9 million, according to the Bloomberg Consensus.
The company’s MACI (matrix-induced autologous chondrocyte implant) net revenue was within the range of $68.2 million to $68.7 million, slightly surpassing the estimate of $68.1 million.
However, the preliminary Epicel (cultured epidermal autografts) net revenue was about $6 million, which was lower than the estimated $8.38 million. The preliminary NexoBrid revenue was about $1 million, under the estimated $1.47 million.
For the year ahead, Vericel predicts an adjusted Ebitda margin of 25% to 26%. The company also expects a gross margin in the range of 73% to 74%, which is slightly higher than the estimated 72.4%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
